Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

NCT ID: NCT02372292

Last Updated: 2015-06-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2015-06-30

Brief Summary

Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Conditions

Cardiorenal Syndrome

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: SINGLE

Study Groups

Group 1

Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.

Group Type: ACTIVE_COMPARATOR

intravenous furosemide

Intervention Type: DRUG

Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Group 2

Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.

Group Type: ACTIVE_COMPARATOR

intravenous furosemide

Intervention Type: DRUG

Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Interventions

intravenous furosemide

Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Intervention Type: DRUG

Other Intervention Names

Lasix

Eligibility Criteria

Inclusion Criteria

• Decompensated heart failure
• Elevated serum creatinine levels on admission

Exclusion Criteria

• Atrial fibrillation
• Obstructive uropathy
• Patients with ascites
• Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents)
• Patients who needed positive inotropic agents

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ankara University

OTHER

Sponsor Role: lead

Responsible Party

Özgür Ulaş Özcan

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Ankara University School Of Medicine, Department of Cardiology

Ankara, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

Ankararenal

Identifier Type: -

Identifier Source: org_study_id